Biofuel IPOs Lackluster of Late

by: Greentech Media

By Michael Kanellos

Kior Lowers IPO Price, But Stock Still Flat

Biofuels appear to be losing their appeal with investors.

Kior (NASDAQ:KIOR), a company that claims it can make a synthetic version of petroleum out of wood and farm waste, sold 10 million shares of stock in an IPO yesterday for $15 a share, lower than the $19 to $21 price it had earlier anticipated.

Friday, on the first day of trading, the stock snoozing at $15.00.

The relatively uneventful IPO, in part, can be chalked up to the fact that Kior, like other biofuel startups going public, is not profitable, is not in commercial production, and will still need hundreds of millions more in capital to scale up to commercial production. Kior lost $45.9 million in fiscal 2010.

Add on top of that the recent events in Washington. The U.S. Senate last week voted 72 to 37 to eliminate the 45 cent per gallon tax credit on biofuel and the 54 cent per gallon tariff on imported ethanol. The Senate action isn't law, but it has received support from both conservative tax groups and environmental organizations. The G-20 is also asking Washington to eliminate biofuel support. Yes, ironies abound. Some conservative groups have opposed eliminating tax credtis for fossil fuel companies, despite recent record profits, and the G-20 has rarely met an agricultural price support policy it doesn't like, but such is life.

Biofuel and biochem companies have enjoyed a mini-boomlet until now. Gevo (NASDAQ:GEVO), which makes a renewable form of isobutanol, went public at $15 a share in February and it rose to $26 a share. Gevo CEO Patrick Gruber told us to months ago that the company planned on expanding production to 350 million gallons by 2015. Gevo just broke ground on an 18 million gallon facility.

The stock, however, is now back at $15.

Solazyme (SZYM), which produces chemicals, food additives and fuel from algae, held its IPO in May, selling its shares at $18 per share. (Earlier it anticipated getting $15 to $17.). It went up to nearly $21 on the first day of trading, but now hovers again at around $20.

Codexis (NASDAQ:CDXS) went public at $11 last year and trades at $9.

Only Amyris (NASDAQ:AMRS), which has a microbe that can convert farm and wood waste into a hydrocarbon called biofene that can be used as an ingredient in a number of substances, has seemingly defied gravity. It went public at $17 last year and is selling for around $29.

Image Credit: flickr, jurvetson